Imago Pharmaceuticals, Inc. is a virtual company developing novel small molecule therapies for neurodegenerative, inflammatory and autoimmune diseases.
Imago was founded by the ex-scientific team of Elan Corporation. In 2013, Elan was acquired by Perrigo and later its JNK based preclinical research pipeline with a huge small molecule drug library, along with research tools were transferred to Imago.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]
Imago is focused on developing small molecule inhibitors against stress-activated kinases. The Jun N-terminal kinase (JNK) has long been recognized as a promising target having potential disease-modifying activity in numerous diseases. Its preclinical programs includes small molecules targeting LRRK2, PLK2, BACE, Gamma-Secretase and AD Neurotoxicity.
In Sep. 2014, Imago acquired a portfolio of preclinical research assets, from Perrigo Company plc., the assets transferred also includes a 500,000 compound CNS-focused small-molecule library.
May 2016, Cure SMA has awarded a $300,000 drug discovery grant to Charlotte Sumner, MD, at Johns Hopkins University, in collaboration with Imago Pharmaceuticals for the Preclinical Development of a JNK Drug Candidate to Alter Disease Progression in SMA.
In May 2015, The Michael J. Fox Foundation for Parkinsons Research (MJFF) acquired the library of research tools around the parkin protein from Imago Pharmaceuticals. Mutations in the parkin (PARK2) gene are associated with young-onset Parkinsons disease and lead to dysfunction of the parkin protein.
Recover your password.
A password will be e-mailed to you.